7799 Herong Tech: IND Application for B10 L-BPA Injection
Herong Tech has filed an Investigational New Drug (IND) application with the TFDA for its B10 L-BPA injection, targeting recurrent locally advanced or metastatic triple-negative breast cancer to evaluate the efficacy and safety of BNCT.
📋 Article Processing Timeline
- 📰 Published: May 26, 2026 at 06:31
- 🔍 Collected: May 26, 2026 at 06:31 (0 min after Published)
- 🤖 AI Analyzed: May 31, 2026 at 20:21 (133h 49m after Collected)
Herong Tech announced that it has filed an Investigational New Drug (IND) application with the Taiwan Food and Drug Administration (TFDA) for its B10 L-BPA injection. The study aims to evaluate the efficacy and safety of Boron Neutron Capture Therapy (BNCT) for recurrent locally advanced or metastatic triple-negative breast cancer. This is a Phase II clinical trial. Triple-negative breast cancer remains one of the most challenging areas in oncology with high unmet medical needs. If successful, this could expand the application of BNCT in solid tumors and create new growth opportunities. The trial is primarily for academic and medical research purposes, with the company acting as the sponsor.
FAQ
What is BNCT?
Boron Neutron Capture Therapy, a targeted radiation therapy for cancer.